Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ

PURPOSE: Ductal carcinoma in situ (DCIS), is a noninvasive breast cancer, representing 20-25% of breast cancer diagnoses in the USA. Current treatment options for DCIS include mastectomy or breast-conserving surgery (BCS) with or without radiation therapy (RT), but optimal risk-adjusted treatment se...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabbs, David, Mittal, Karuna, Heineman, Scott, Whitworth, Pat, Shah, Chirag, Savala, Jess, Shivers, Steven C., Bremer, Troy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236475/
https://www.ncbi.nlm.nih.gov/pubmed/37274253
http://dx.doi.org/10.3389/fonc.2023.1069059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236475/
https://www.ncbi.nlm.nih.gov/pubmed/37274253
http://dx.doi.org/10.3389/fonc.2023.1069059

Ejemplares similares